Concepedia

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

Meletios Α. Dimopoulos, Vânia Hungria, Atanas Radinoff, Sosana Delimpasi, Gábor Mikala, Tamás Masszi, Marcelo Capra, Ângelo Maiolino, Vasiliki Pappa, Dominik Chraniuk,

The Lancet Haematology · 2023 · 124 citations · 15 references

DOI

Concepts

References

15

Interpreting the significance of changes in health-related quality-of-life scores.

David Osoba, George Rodrigues, James D. Myles et al. · Journal of Clinical Oncology · 1998 · 2.9K citations

, , +16

BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells

Brian P. O’Connor, Vanitha S. Raman, Loren D. Erickson et al. · The Journal of Experimental Medicine · 2004 · 1.1K citations · Full text

, , +14

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 796 citations

, , +11

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

Ujjawal H. Gandhi, Robert F. Cornell, Arjun Lakshman et al. · Leukemia · 2019 · 616 citations

, , +13

Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

Kim Cocks, Madeleine King, Galina Velikova et al. · European Journal of Cancer · 2012 · 565 citations · Full text

, , +15